2026 年最值得关注的药物预测
科睿唯安2026-01-12129 页
FDA’s Rare Disease Evidence Principles (RDEP): Use Real-World Evidence in Ultra-Rare Drug Development
IQVIA2026-01-237 页
2025全球罕见病行业发展报告:政策演进、市场趋势与领先企业布局
摩熵咨询2026-02-0342 页
#JPM2026 Post JPM Report
Biomedtracker (Evaluate, a Norstella company)2026-02-05115 页
Impacts of the Proliferation of Innovation
IQVIA Institute for Human Data Science2026-02-1353 页
全球在研新药月报—2026年1月
摩熵·咨询2026-02-1436 页
Advancing Equitable and Timely Access to Personalized Oncology Therapies: Middle East and Africa
IQVIA Institute for Human Data Science2026-03-2612 页